Literature DB >> 26714212

Warfarin and Vascular Calcification.

Timothy J Poterucha1, Samuel Z Goldhaber2.   

Abstract

The vitamin K antagonist, warfarin, is the most commonly prescribed oral anticoagulant. Use of warfarin is associated with an increase in systemic calcification, including in the coronary and peripheral vasculature. This increase in vascular calcification is due to inhibition of the enzyme matrix gamma-carboxyglutamate Gla protein (MGP). MGP is a vitamin K-dependent protein that ordinarily prevents systemic calcification by scavenging calcium phosphate in the tissues. Warfarin-induced systemic calcification can result in adverse clinical effects. In this review article, we highlight some of the key translational and clinical studies that associate warfarin with vascular calcification.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; Matrix gamma-carboxyglutamate Gla protein; Vascular calcification; Warfarin

Mesh:

Substances:

Year:  2015        PMID: 26714212     DOI: 10.1016/j.amjmed.2015.11.032

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  22 in total

1.  Reversible cerebral vasoconstriction syndrome and antivitamin K anticoagulation: challenges of an unusual association.

Authors:  Amina Nasri; Malek Mansour; Amel Kacem; Jamel Zaouali; Ridha Mrissa
Journal:  Neurol Sci       Date:  2017-05-13       Impact factor: 3.307

2.  Vitamin K Status, Warfarin Use, and Arterial Stiffness in Heart Failure.

Authors:  Zeba Hashmath; Jonathan Lee; Swetha Gaddam; Bilal Ansari; Garrett Oldland; Khuzaima Javaid; Anique Mustafa; Izzah Vasim; Scott Akers; Julio A Chirinos
Journal:  Hypertension       Date:  2019-02       Impact factor: 10.190

Review 3.  Role of direct oral anticoagulants in patients with kidney disease.

Authors:  Vimal K Derebail; Michelle N Rheault; Bryce A Kerlin
Journal:  Kidney Int       Date:  2019-12-24       Impact factor: 10.612

4.  Stabilization of warfarin-binding pocket of VKORC1 and VKORL1 by a peripheral region determines their different sensitivity to warfarin inhibition.

Authors:  G Shen; S Li; W Cui; S Liu; Q Liu; Y Yang; M Gross; W Li
Journal:  J Thromb Haemost       Date:  2018-05-20       Impact factor: 5.824

5.  Effects on bone metabolism markers and arterial stiffness by switching to rivaroxaban from warfarin in patients with atrial fibrillation.

Authors:  Sayaka Namba; Minako Yamaoka-Tojo; Ryota Kakizaki; Teruyoshi Nemoto; Kazuhiro Fujiyoshi; Takehiro Hashikata; Lisa Kitasato; Takuya Hashimoto; Ryo Kameda; Kentaro Meguro; Takao Shimohama; Taiki Tojo; Junya Ako
Journal:  Heart Vessels       Date:  2017-02-23       Impact factor: 2.037

6.  Cardiovascular Disease Death Before Age 65 in 168 Countries Correlated Statistically with Biometrics, Socioeconomic Status, Tobacco, Gender, Exercise, Macronutrients, and Vitamin K.

Authors:  David K Cundiff; Paul S Agutter
Journal:  Cureus       Date:  2016-08-24

Review 7.  Calcium regulation of stem cells.

Authors:  Hans-Willem Snoeck
Journal:  EMBO Rep       Date:  2020-05-17       Impact factor: 8.807

Review 8.  Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerations.

Authors:  Jens Lutz; Kerstin Jurk; Helmut Schinzel
Journal:  Int J Nephrol Renovasc Dis       Date:  2017-06-12

9.  Plasma osteopontin versus intima media thickness of the common carotid arteries in well-characterised patients with systemic lupus erythematosus.

Authors:  Lina Wirestam; Muna Saleh; Christina Svensson; Michele Compagno; Helene Zachrisson; Jonas Wetterö; Christopher Sjöwall
Journal:  Lupus       Date:  2021-05-06       Impact factor: 2.911

10.  Safety and effectiveness of apixaban compared to warfarin in dialysis patients.

Authors:  Daniel Reed; Surabhi Palkimas; Rebecca Hockman; Sumner Abraham; Tri Le; Hillary Maitland
Journal:  Res Pract Thromb Haemost       Date:  2018-03-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.